Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

por Girardi, Daniel M., Niglio, Scot A., Mortazavi, Amir, Nadal, Rosa, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa, Ley, Lisa, Ortiz, Olena Sierra, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Hadi, Redd, Bernadette, Steinberg, Seth M., Costello, Rene, Chan, Keith S., Lee, Min-Jung, Lee, Sunmin, Yu, Yunkai, Gurram, Sandeep, Chalfin, Heather J., Valera, Vladimir, Figg, William D., Merino, Maria, Toubaji, Antoun, Streicher, Howard, Wright, John J., Sharon, Elad, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Cao, Liang, Trepel, Jane B., Apolo, Andrea B.
Publicado 2022

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

por Apolo, Andrea B., Nadal, Rosa, Girardi, Daniel M., Niglio, Scot A., Ley, Lisa, Cordes, Lisa M., Steinberg, Seth M., Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Mallek, Marissa, Davarpanah, Nicole N., Costello, Rene, Trepel, Jane B., Lee, Min-Jung, Merino, Maria J., Bagheri, Mohammad Hadi, Monk, Paul, Figg, William D., Gulley, James L., Agarwal, Piyush K., Valera, Vladimir, Chalfin, Heather J., Jones, Jennifer, Streicher, Howard, Wright, John J., Ning, Yangmin M., Parnes, Howard L., Dahut, William L., Bottaro, Donald P., Lara, Primo N., Saraiya, Biren, Pal, Sumanta K., Stein, Mark N., Mortazavi, Amir
Publicado 2020